Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
HaEmek Medical Center, Israel |
---|---|
Information provided by: | HaEmek Medical Center, Israel |
ClinicalTrials.gov Identifier: | NCT00599898 |
The purpose of this study is to investigate the efficacy and the safety of nifedipine compared to atosiban for treating preterm labor.
Condition | Intervention | Phase |
---|---|---|
Labor, Premature |
Drug: Atosiban Drug: Nifedipine |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Crossover Assignment, Safety/Efficacy Study |
Official Title: | Nifedipine Compared to Atosiban for Treating Preterm Labor. A Randomized Controlled Trial. |
Estimated Enrollment: | 140 |
Study Start Date: | January 2008 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Atosiban
Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
|
2: Experimental |
Drug: Nifedipine
Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
|
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
All women fulfilled the criteria of preterm labor. The diagnosis of preterm labor required the presence of 4 uterine contractions or more over 30 minutes, each lasting at least 30 seconds, and documented cervical change. The cervical criteria were met when either of the following was present:
Exclusion Criteria:
Maternal contraindications
Contact: Gali Garmi, MD | 972-4-6494031 | galit_ga@clalit.org.il |
Contact: Raed Salim, MD | 972-4-6494035 | salim_ra@clalit.org.il |
Israel | |
HaEmek Medical Center | Recruiting |
Afula, Israel, 18100 | |
Contact: Gali Garmi, MD 972-4-6494031 galit_ga@clalit.orgil | |
Contact: Raed Salim, MD 972-4-6494035 salim_ra@clalit.orgil |
Principal Investigator: | Gali Garmi, MD | HaEmek Medical Center, Afula, Israel |
Responsible Party: | HaEmek Medical Center, Israel ( Dr. Gali Garmi ) |
Study ID Numbers: | EMC070048CTIL, same as unique protocol ID |
Study First Received: | January 8, 2008 |
Last Updated: | July 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00599898 |
Health Authority: | Israel: Ethics Commission; Israel: Ministry of Health |
Preterm labor Atosiban Nifedipine |
Calcium, Dietary Pregnancy Complications Atosiban Obstetric Labor, Premature |
Indomethacin Obstetric Labor Complications Nifedipine |
Membrane Transport Modulators Vasodilator Agents Tocolytic Agents Molecular Mechanisms of Pharmacological Action Hormone Antagonists Therapeutic Uses |
Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Calcium Channel Blockers Reproductive Control Agents Cardiovascular Agents Pharmacologic Actions |